OPTN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:14):

Stats
Today's Volume	1.75M
Average Volume	991 833
Market Cap	96.58M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.77
ATR14	$0.00400 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Krick Anthony J	Sell	2 345	Common Stock
2024-03-15	Marino Michael F Iii	Buy	3 816	Common Stock
2024-03-18	Marino Michael F Iii	Sell	15 059	Common Stock
2024-03-15	Mahmoud Ramy A	Buy	6 114	Common Stock
2024-03-18	Mahmoud Ramy A	Sell	19 198	Common Stock

INSIDER POWER
-24.23
Last 98 transactions
Buy: 6 923 187 \| Sell: 11 541 596

Volume Correlation

Long: 0.02 (neutral)

Short: 0.99 (very strong)

Signal:(68.712) Expect same movement, but be aware

OptiNose Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OptiNose Inc Correlation - Currency/Commodity

0.25
( neutral )

-0.24
( neutral )

0.00
( neutral )

0.42
( neutral )

0.00
( neutral )

0.16
( neutral )

OptiNose Inc Financials

Annual	2023
Revenue:	$70.99M
Gross Profit:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2023
Revenue:	$70.99M
Gross Profit:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2022
Revenue:	$76.28M
Gross Profit:	$67.01M (87.86 %)
EPS:	$-0.890

FY	2021
Revenue:	$74.65M
Gross Profit:	$65.50M (87.74 %)
EPS:	$-1.450

Financial Reports:

No articles found.

OptiNose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.